FDA is reviewing 7 peptides. Here's what changes at your bench

When a U.S. Food and Drug Administration advisory panel schedules a review of specific peptides, researchers who work with these compounds need to pay attention. The chemistry of the peptides doesn't change. The sourcing environment does.

The FDA's Pharmacy Compounding Advisory Committee, known as PCAC, examines whether particular substances can legally be used by compounding pharmacies. Compounding pharmacies are specialized facilities that mix and prepare custom formulations, rather than simply dispensing manufactured drugs. When the panel votes that a compound fails the criteria for compounding, those pharmacies lose the legal basis to prepare it. Supply chains shift, sometimes quickly.

How the FDA Compounding Review Actually Works

Compounding in the U.S. runs under two main frameworks. 503A covers pharmacies compounding for individual patients on a prescription-by-prescription basis. 503B covers larger outsourcing facilities producing batch quantities. Both frameworks require that the bulk substances used are either in an already FDA-approved drug product, or explicitly included on a permitted list.

The PCAC weighs each substance against a specific set of criteria. A compound qualifies for compounding if there is documented clinical need, if no commercially manufactured equivalent in a suitable form already exists, or if a shortage applies. Peptides frequently land in a gray zone: many have been used in compounding for years without formal PCAC review, sitting between "approved drug" and "unapproved bulk substance."

A committee review doesn't automatically mean a ban. The PCAC can recommend inclusion on the approved list, which formalizes access, or it can recommend exclusion. Either outcome has downstream effects for researchers sourcing from compounding channels.

Why Peptide Popularity Triggered This Review

Peptide research has expanded across a wide range of compound classes in recent years. Compounds like BPC-157, thymosin beta-4, and various growth hormone secretagogues (peptides that signal the pituitary gland to release growth hormone) have moved from narrow research use into much wider commercial circulation. That volume created a substantial compounding market, which created regulatory visibility.

The FDA's concern is about quality, consistency, and the boundaries of the compounding exemption. The compounding framework was designed for individualized patient preparations, not large-scale production of compounds that function similarly to manufactured drugs. When a compounded peptide is being prepared at scale, regulators start asking whether compounding is still the right category.

For researchers, the distinction matters because sourcing channel affects documentation. A peptide sourced from a compounding pharmacy comes with batch records and USP (United States Pharmacopeia, the body that sets quality standards for drugs and ingredients) compliance requirements. A research-chemical supplier operates under a different, less standardized framework. Neither is automatically better for your bench work, but they come with different verification burdens.

What Shifts for Purity and Sourcing

Regulatory uncertainty puts more pressure on researchers to verify what they're actually working with. If compounding access tightens for a peptide you use, sourcing may shift toward suppliers with less standardized documentation. That's when COA scrutiny becomes most important.

• HPLC purity: High-performance liquid chromatography separates every component in a sample and measures each one. A research-grade peptide COA (certificate of analysis) should show purity of at least 98% by HPLC. Below that, impurities can introduce variables that confound your results.
• Mass spectrometry confirmation: This test verifies the peptide has the correct molecular weight, confirming you have the right compound, not a contaminant or substitute.
• Third-party testing: A COA generated by the same company that manufactured the peptide carries less weight than one from an independent laboratory. Ask who ran the tests.
• Endotoxin testing: Endotoxins are toxic fragments from bacterial cell walls that can contaminate peptide samples during manufacturing. A clean endotoxin result is a marker of careful production.

Practical Steps While the Regulatory Picture Settles

The best thing you can do while this review plays out is tighten your sourcing documentation and cold-storage discipline. Regulatory reviews can take months. In the meantime, the peptides on the committee's list remain available through appropriate research-supply channels, but the supply landscape for any given compound could change.

Keep lyophilized (freeze-dried, powder-form) peptides at -20 degrees Celsius. Once reconstituted in bacteriostatic water (sterile water containing 0.9% benzyl alcohol, which slows bacterial growth and extends sample stability), store at 2-8 degrees Celsius and away from light. Most reconstituted peptides prepared in bacteriostatic water remain stable for up to four weeks refrigerated, though this varies by compound. Label every vial with the reconstitution date and concentration.

If your workflow uses a peptide that might be under review, stock lyophilized material now rather than waiting. Powder is more stable in cold storage and gives you more time to sort out sourcing if availability shifts. Document your current supplier's COA for each lot so you have a purity baseline to compare against future batches.

The FDA panel review is administrative, not scientific. It will not change what these peptides are or how they behave in your samples. It will change where your samples come from and what paperwork comes with them.

Frequently asked questions

What happens to peptide availability if the FDA restricts compounding?

Compounding pharmacies lose the legal basis to prepare that compound, pushing sourcing toward research-chemical suppliers. Researchers should verify HPLC purity, mass spec confirmation, and third-party COAs before switching sources.

How do I verify a research peptide's purity before using it?

Request a COA showing HPLC purity of at least 98%, mass spectrometry confirmation of the correct molecular weight, and ideally endotoxin test results. COAs from independent third-party labs carry more weight than manufacturer-issued ones.

Does an FDA regulatory review change how I should reconstitute or store a peptide?

No. Reconstitution protocol depends on the peptide's chemistry. Use bacteriostatic water or dilute acetic acid as appropriate, store reconstituted samples at 2-8°C, and keep lyophilized powder at -20°C until needed.

Prompted by this coverage at Google News →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

What the research community gets wrong about the FDA peptide compounding review

A committee review touches paperwork and sourcing, not the molecule in your vial. Here are the assumptions that trip people up at the bench.

• A review is not the same as a ban. The PCAC can recommend adding a substance to the approved compounding list just as easily as recommending against it. Reading every scheduled review as a coming shortage leads to panic sourcing that is not backed by the actual outcome.
• The review does not change the peptide. The molecular weight, the sequence, and how the material behaves once reconstituted in your vial stay the same. What can change is where a lot comes from and what documentation ships with it, so your verification habits matter more than the headline.
• "Pharmacy grade" or "compounded" does not automatically mean higher purity for your work. Compounding compliance is built around preparing a drug, not around the research-grade metrics you check on a bench. Whatever the channel, you still confirm identity and purity yourself from the certificate of analysis.
• A certificate of analysis from the maker is not third-party verification. Many people treat any COA as proof. Who ran the test is the part that counts. A result from an independent lab carries more weight than one generated by the same company that sold the lot.
• Stockpiling powder is not the same as stockpiling ready-to-use material. Lyophilized powder held cold is far more stable over time than material already reconstituted in bacteriostatic water. Assuming a reconstituted vial will keep for the same span as sealed powder is a common storage error.

From our bench: If you have compared certificates of analysis from two suppliers for the same peptide, tell us what you found. Did the reported HPLC purity hold up when you or an independent lab re-tested the lot, and did the mass spec confirm the expected molecular weight? Share the actual figures from your own records, not estimates, so other researchers can see how sourcing channel lined up with what was in the vial.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins